Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD After Allogeneic Hematopoietic Stem Cell Transplantation

NCT06244628 is registered in ClinicalTrials.gov with Xuzhou Medical University as lead sponsor.

NCT NCT06244628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06244628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD After Allogeneic Hematopoietic Stem Cell Transplantation
Lead sponsor
Xuzhou Medical University
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 10, 2024
Completion date
December 31, 2028
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cgvhd